1Stringer MD, Gorog PG, Freeman A, et al. Lipid peroxides and atherosclerosis[J]. Br Med J, 1989,298:281.
2Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease[J]. Clin Chem, 1994,40(1) :18.
3Breimez LH, Wannamethee G, Ebrabim S, et al. Serum bilirubin and rish of ischemic heart disease in middle- aged British men [J]. Clin Chem, 1995,41(10) :1504.
4Fricker J. A vaccine approach to healthy lipoprotein levels. Mol Med To day, 1999,5(7) :281.
5O' Bfien C. Vaccine for atherescleresis. Mol-Med-Today, 1997,3(6): 231.
6Charles W. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherescleresis. Arterioscler Thromb Vasc Biol,2000,9:2106-2112.
7Ross R. Atherescler, osis-an inflammatory disease. N Engl J Med, 1999, 340:115-126.
8Bruemmer D, Riggers U, Holzmeister J, et al. Expression of CD40 invascular smooth muscle cells and macrophages is associated with early development of human atherescleretic lesions. Am J Cardiol, 2001,87: 21-27.
9Hakkinen T, Karkola K, Yla-Herttuala S, et al. Macrophages, smooth muscle cells,endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atheresclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16. Virehows Areh,2000,437:396-405.
10Kapsas M , Hsu YM , Wang JH , et al . 2 A crystal structure ! of an extracelluar fragment of human CD40 ligand. Structure, 1995,3:1031-1039.
